Rice Biotech Launchpad leads commercialization of ROGUE treatment for obesity, type 2 diabetes
The Advanced Research Projects Agency for Health (ARPA-H) has awarded more than $34 million to accelerate the development of a bioelectronic implant designed to improve adherence for obesity and type 2 diabetes (T2D) treatment while reducing development and manufacturing costs.
